Table 3.
Family 1 | Family 2 | Family 3 | Family 4 | Family 5 | Family 6 | Family 7 | |||||
---|---|---|---|---|---|---|---|---|---|---|---|
II-2 | II-3 | II-3 | II-4a | II-1 | II-3 | II-3 | II-4 | III-1 | II-5 | ||
Neurophysiological studies (EEG) | |||||||||||
Diffuse background slowing | + | + | + | + | − | + | − | N/A | − | + | 6/10 |
Epileptiform activity | + | + | + | + | − | − | − | + | − | + | 6/10 |
LTM-EEG | Frequent tonic seizures with eyelid myoclonia over 48 h | 20 GTC and 4 focal seizures over 24 h | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Frequent generalized myoclonic and tonic seizures over 48 h | |
Brain imaging | |||||||||||
Study type | Brain MRI | Brain MRI | Brain MRI | Brain MRI | Brain MRI | Brain MRI | Head CT | Head CT | Brain MRI | Brain MRI | |
Cerebral atrophy | + | + | − | + | − | + | − | − | + | − | 5/10 |
Cerebellar atrophy | + | + | − | − | − | − | − | − | − | − | 2/10 |
CC abnormality | + | + | + | + | − | + | − | − | + | − | 6/10 |
Under-opercularization | + | + | − | + | − | − | − | + | + | + | 6/10 |
Abnormal myelination | + | + | − | + | − | + | − | − | + | + | 6/10 |
Others | Thin brainstem | Generous extra-axial CSF spaces | – | Dolichocephaly, mild posterior plagiocephaly | Generous extra-axial CSF spaces; mild superior vermian hypoplasia | Generous extra-axial CSF spaces | |||||
Brain MRS findings | Low NAA and Glx peaks | Lactate peak | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
Metabolic laboratory studies | |||||||||||
Plasma lactate and pyruvate | Normal | Transient elevation of lactate | Transient metabolic acidosis (due to TPM use) | Transient elevation of lactate and pyruvate | Transient elevation of lactate and pyruvate | Normal | Slightly elevated lactate | Transient elevation of lactate; normal pyruvate | Elevated lactate | Transient elevation of lactate | |
Plasma ammonia | Normal | Elevated (62 µmol/l) | N/A | N/A | Normal (25 µmol/l) | N/A | Elevated (52 µmol/l) | Elevated (56 µmol/l) | Elevated (87 µmol/l) | Normal (44 µmol/l) | |
PAA | Normal | Normal | Normal | Normal | Normal | Normal | Normal | Normal | Normal | Normal | |
UOA | Normal | Normal | Normal | N/A | Normal | Normal | Normal | Normal | Normal | Normal | |
CSF amino acids | Normal | Normal | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
CSF neurotransmitters | Normal | Normal | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
CSF lactate | N/A | Normal | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
CC = corpus callosum; c/w = consistent with; Glx = glutamate-glutamine; GTC = generalized tonic-clonic; LTM-EEG = long-term monitoring EEG; MRS = magnetic resonance spectroscopy; NAA = N-acetylaspartate; N/A = not available; PAA = plasma amino acids; TPM = topiramate; UOA = urine organic acids.
Previously published with limited clinical data.